AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04993287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive continuous remote monitoring with structured escalation pathway
Description: Continuous patient monitoring through non-invasive biosensors coupled with machine learning algorithms, with a structured escalation and communication pathway for home health providers and HF care team
Study NCT04993287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
Description: Surveys and interviews with enrolled participants
Study NCT06041269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosnilimab
Description: PD-1 agonist antibody
Study NCT06041269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06016231 — intervention group
Intervention type: DEVICE
Intervention: Light Adjustable Lens
Description: The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power.
Study NCT05226962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A liquid placebo that is volume- and taste-matched to the ketone monoester supplement
Study NCT05978817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Damon Ultima bracket
Description: It is metal twin bracket with their recommended arch wire
Study NCT05060913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA Cream
Description: Effect of 5% Emla cream on pricking pain measured on VAS scale.
Study NCT05060913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine Gel
Description: Effect of 20% Benzocaine gel on pricking pain measured on VAS scale.
Study NCT06134687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Submucosal Dissection
Description: Removal of study eligible lesions per endoscopic submucosal dissection
Study NCT06134687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Submucosal Dissection
Description: Removal of study eligible lesions per endoscopic submucosal dissection
Study NCT06134687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Rigidizing Overtube
Description: Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection
Study NCT04980066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sticky bone and EDTA
Description: treatment using Sticky bone after EDTA root surface biomodification
Study NCT04980066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sticky bone
Description: treatment using Sticky bone
Study NCT05065957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D07001-softgel capsules + Xeloda (or TS-1)
Description: D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)
Study NCT05065957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D07001-softgel capsules + Xeloda (or TS-1)
Description: D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)
Study NCT05065957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX
Description: intravenous infusion on Day 1 for 14-day cycle
Study NCT06568406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Examination by a physiotherapist: the first check-up with an examination and a therapeutic intervention with the patient is performed within 24-72 hours after delivery. This is followed by two regular outpatient check-ups by a physiotherapist for the purpose of therapy and education. The second check takes place after 6-8 weeks. And the third check occurs after 10-14 weeks after childbirth. In these three checks, data collection is carried out simultaneously (in order to complete the secondary objective). The patients are examined and monitored by the same physiotherapist.
Study NCT06568406 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urogynaecology
Description: Examination by a urogynaecologist this is carried out in the period of 14-18 weeks after childbirth in order to complete the primary objective. Data collection in order to complete the primary objective is done in the period of 14-18 weeks and 12-14 months after delivery (the online method without the need for a physical visit is preferred).
Study NCT06568406 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urogynaecology
Description: Examination by a urogynaecologist this is carried out in the period of 14-18 weeks after childbirth in order to complete the primary objective. Data collection in order to complete the primary objective is done in the period of 14-18 weeks and 12-14 months after delivery (the online method without the need for a physical visit is preferred).
Study NCT06543251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training group (HIIT)
Description: The participants performed HIIT programs for 12 weeks involving walking/running on a treadmill preceded by a 10-min warm-up at low intensity and exercise with high intensity for 1 min at 85%-90% of the maximum heart rate alternating with low intensity at 50%-55% of the maximum heart rate for 2 min, for 24 minutes, and 10-min cool down.
Study NCT05004727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
Study NCT05004727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab
Description: Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
Study NCT05004727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: • Placebo to Guselkumab 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (Month 0 to Week 20 for Arm 2).
Study NCT05166291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort-in injection system
Description: local anesthesia applyed with comfort-in injection system
Study NCT05166291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional anesthesia
Description: local anesthesia applyed with dental syringe
Study NCT04136834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PT01 (Pegtomarginase)
Description: PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
Study NCT05612516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of hydrogen peroxide levels in saliva using trays with reservoir.
Description: During bleaching using trays with reservoir.
Study NCT05612516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of hydrogen peroxide levels in saliva using trays without reservoir.
Description: During bleaching using trays without reservoir.
Study NCT06543251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate continuous training group (MCT)
Description: Subject participating in 30-min sessions for 12 weeks and Each session consisted of a 10-min warm up, walking/running on a treadmill 30 minutes at 65-70% Maximum Heart rate and 10-min cool down.
Study NCT06543251 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sedentary control group (CON)
Description: The control group had normal daily life.
Study NCT05123040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 MG Oral Tablet
Description: By mouth twice daily through day 56, then tapered
Study NCT05123040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: 2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
Study NCT05123040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg
Study NCT05558007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: Daily oral administration of tadalafil 5mg
Study NCT05558007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BZ371A
Description: Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
Study NCT05558007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A
Description: Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
Study NCT05558007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral administration of a placebo pill
Study NCT05558007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Placebo
Description: Topical application of 1.5 mL of placebo
Study NCT05523102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol/acetaminophen
Study NCT06643975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-piece zirconia dental implants
Description: One-piece zirconia dental implants with zirconia ball attachments, these implants are metal free made of oxide ceramics with cutting-edge Selective laser melting(SLM) surface treatment technology
Study NCT05523102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Intravenous ketorolac/NSAID
Study NCT06643975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-piece titanium dental implants
Description: One-piece Titanium dental implants with titanium ball attachments, these implants are gold standard compatible implants
Study NCT06650540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Plus Metronidazole Suppositories
Description: Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.
Study NCT06650540 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin co-administered with Metronidazole tablets
Description: Administer a two-week course of Levofloxacin in combination with Metronidazole tablets to patients diagnosed with chronic endometritis.
Study NCT06649734 — intervention group
Intervention type: OTHER
Intervention: Delphi Study
Description: A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
Study NCT01585090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: doing strengthening exercises of pelvic floor muscles
Study NCT01585090 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: doing strengthening exercises of pelvic floor muscles
Study NCT05823285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31903
Description: 0.01μg/kg-2.16 μg/kg QLS31903 for injection
Study NCT05653557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shen Que Moxibustion
Description: Herb-partitioned moxibustion was administered at RN8 (Shen Que), once every 72 hours from the beginning of previous menstrual cycle day 2 until oocyte retrieval. Approximately 10 moxa cones will be used for this procedure, which will take approximately two hours. It is recommended that patients close their eyes during the procedure and rest. Following moxibustion, the umbilicus will be affixed and sealed with a medical applicator and removed after 24 hours.
Study NCT05700942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Dose Intervention-tsDCS
Description: Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)
Study NCT05700942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Intervention-tsDCS
Description: Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
Study NCT06470737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.2 mL
Study NCT06470737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop
Study NCT06470737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
Study NCT04649008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3T Magnetic Resonance Imaging
Description: Magnetic resonance imaging acquired at a field strength of 3 Tesla.
Study NCT04649008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intracranial electroencephalography recordings
Description: Epilepsy patients may undergo implantation of intracranial electroencephalography (iEEG) electrodes for localization of epileptogenic foci, which also provide a means to record localized brain activity during memory or other tasks for research purposes.
Study NCT04649008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 7T Magnetic Resonance Imaging
Description: Magnetic resonance imaging acquired at a field strength of 7 Tesla.
Study NCT06470737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMS-evoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
Study NCT06652126 — intervention group
Intervention type: OTHER
Intervention: Microbiological examinations.
Description: * BMR testing by rectal swab (combined with nasal swab in some centers) on admission to the ICU and weekly as part of routine care.~* Microbiological samples (blood cultures, respiratory and urinary samples, etc.) as part of routine care at the request of the clinicians in charge of the patient.
Study NCT06653478 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT05505591 — intervention group
Intervention type: DRUG
Intervention: Cangrelor
Description: Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes
Study NCT06653517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule.
Study NCT06653517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule.
Study NCT06653452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan
Description: Patients with Locally Advanced Rectal Cancer underwent 68Ga-FAPI-04 PET/CT and PET/MR scan after injection of 0.02 to 0.04 mCi/Kg×patient weight (Kg). Within 1 week before and after the examination, 18F-FDG PET/CT and PET/MR is completed.
Study NCT06494059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta burst stimulation (iTBS)
Description: iTBS is a magnetic stimulation applied using a magnetic coil that is placed on top of the participants head to activate the brain. It consists of three very rapid bursts of electrical pulses at a frequency of 50 Hz (per burst) delivered at a rate of 5 per second for 2 seconds (10 bursts). The burst of pulses will be repeated every 10 seconds for a total duration of about 3 minutes. The stimulation will be applied to activate the brain regions that control upper limb, lower limb or trunk muscles. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
Study NCT06494059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Description: iTBS is a magnetic stimulation applied using a magnetic coil that is placed on top of the participants head to activate the brain. It consists of three very rapid bursts of electrical pulses at a frequency of 50 Hz (per burst) delivered at a rate of 5 per second for 2 seconds (10 bursts). The burst of pulses will be repeated every 10 seconds for a total duration of about 3 minutes. The stimulation will be applied to activate the brain regions that control upper limb, lower limb or trunk muscles. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
Study NCT06494059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional electrical stimulation (FES)
Description: FES is applied using electrodes that stick to the skin over the muscles or nerves. It will will be applied using an electrical stimulator to produce movements of the hand, leg or the trunk. The stimulation intensity will be determined by gradually increasing strength from 20-100 hertz (hz) until the right amount of movement is obtained. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
Study NCT06494059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Description: FES is applied using electrodes that stick to the skin over the muscles or nerves. It will will be applied using an electrical stimulator to produce movements of the hand, leg or the trunk. The stimulation intensity will be determined by gradually increasing strength from 20-100 hertz (hz) until the right amount of movement is obtained. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
Study NCT06494059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous spinal cord stimulation (TSCS)
Description: TSCS is applied using electrodes that stick to the skin over the spinal cord to activate spinal cord. Mild electrical stimulation will be applied to make sure the nerves on the back are activated (switched on). Different stimulation intensities (strength) will be tested at different frequencies (pulses per second) to determine the best setting for activating the nerves on the back. The stimulus current strength will be adjusted between 0-250 milliamperes (mA) and will remain within the self-reported tolerance limit of each participant. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
Study NCT06494059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation (TSCS)
Description: TSCS is applied using electrodes that stick to the skin over the spinal cord to activate spinal cord. Mild electrical stimulation will be applied to make sure the nerves on the back are activated (switched on). Different stimulation intensities (strength) will be tested at different frequencies (pulses per second) to determine the best setting for activating the nerves on the back. The stimulus current strength will be adjusted between 0-250 milliamperes (mA) and will remain within the self-reported tolerance limit of each participant. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
Study NCT06494059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Intermittent theta burst stimulation (iTBS)
Description: Subjects will be fitted with a magnetic coil that is placed on top of the head that does not deliver any stimulation to the brain. Each subject is expected to participate longitudinally at least 9 times over 2 months.Each visit will take approximately 2-3 hours.